Streetbeat News

Earnings

TEVA

Teva Pharmaceutical Industries announced successful results from a Phase 3 study of AJOVY, meeting all critical efficacy endpoints through hierarchical testing, indicating significant efficacy and safety.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:38 pm

ACHR

BTU

GERN

HZO

TTD

UEC

Jim Cramer shared his views on several stocks on CNBC's 'Mad Money Lightning Round,' recommending against MarineMax due to risk and Peabody Energy because of his stance on coal, while praising Trade Desk and showing interest in Uranium Energy. He was neutral on Geron Corp, citing better biotech options, and found Archer Aviation too speculative. Notable company updates include stock repurchase programs, earnings reports, and executive appointments.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 12:38 pm

JPM

JPMorgan Chase & Co. (JPM) is anticipated to report Q1 earnings with an increase in both earnings per share and revenue compared to the previous year. The article also explores how investors can generate monthly income from JPMorgan's dividends, detailing the number of shares needed to achieve specific monthly income targets. Additionally, it mentions the fluctuating nature of dividend yields with stock price changes and the impact of dividend payment adjustments.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 12:33 pm

SPY

The Core Producer Price Index (PPI) for March increased by 2.4% year-over-year, surpassing the estimated 2.3% and the previous month's 2%. This indicates a slight acceleration in the price producers receive for their goods and services, excluding food and energy prices.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:31 pm

ELYM

RENT

RLYB

Rallybio collaborates with Johnson & Johnson on therapeutics for pregnant individuals at risk of FNAIT, causing RLYB shares to surge by 104%. Rent the Runway's mixed Q4 results and future guidance boost RENT shares by 77%. Eliem Therapeutics announces acquisition of Tenet and a $120 million private placement, leading to a 65% increase in ELYM shares.

Portfolio Pulse from ryanfaloona@benzinga.com

April 11, 2024 | 12:31 pm

SPY

The Core Producer Price Index (PPI) for March increased by 0.2%, aligning with the market expectations.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:30 pm

BTU

Peabody Energy's shares dropped following the announcement of preliminary unaudited Q1 revenue results, which fell below estimates.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:22 pm

ASPI

ASP Isotopes Inc. (ASPI) reported a $(4.7)M operating free cash flow for 2023, slightly better than the $(5)M target. The company ended the year with $7.9M in cash and recently raised over $25.5M through a convertible note offering and warrant exercises. ASPI highlighted its progress, including the start of its first commercial isotopes plant, contracts for enriched silicon-28 and nuclear fuels, and the construction of a quantum enrichment facility. The company expects to generate revenue from enriched isotopes sales this year and is exploring debt financing options for future projects.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:13 pm

LAKE

Lakeland Industries Inc (NASDAQ:LAKE) reported Q4 FY24 sales of $31.20 million, below the analyst consensus of $32.50 million, with a 7.7% Y/Y growth. Gross profit rose 3.2% Y/Y to $11.2 million, but gross margin fell to 35.9% from 37.5%. The company experienced an operating loss of $3.3 million, a downturn from last year's $0.1 million profit. Adjusted EBITDA improved to $3.4 million from $1.9 million. EPS was $(0.13), missing the $0.30 estimate. Lakeland forecasts FY25 revenue of $140 million to $150 million and adjusted EBITDA of $16.8 million to $18.5 million. Shares closed up 1.44% at $17.67.

Portfolio Pulse from Shivani Kumaresan

April 11, 2024 | 12:12 pm

MEIP

MEI Pharma, Inc. (NASDAQ:MEIP) has decided to focus on advancing voruciclib and developing a new formulation of ME-344 based on positive clinical data, foregoing a second capital return under the 2023 Anson and Cable Car Cooperation Agreement to conserve capital. The strategic plan aims to optimize the development of voruciclib for a Phase 3 study in combination with venetoclax for treating relapsed/refractory AML and to enhance ME-344's formulation for treating solid tumors in combination with VEGF inhibitors like Avastin. This decision is aligned with the company's goal to address significant medical needs while managing resources effectively.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:06 pm